1 mg tirzepatide Troubling Findings in Study of GLP-1 Compounders Tirzepatide Research Peptide | >99%

Retatrutide is in clinical trials by Eli Lilly, while MOTS-c is largely available through research channels

Another peptide, GHK-Cu, is being studied for potential cosmetic benefits such as for photoaging and hair loss and was added to the Category 1 list (but not for injectable routes of administration)

10.1001/archinte.168.15.1617 13

Many users report a smoother, more natural-looking colour that lasts longer than sunbed tans alone

Understanding the relationship between these medications and muscle-related symptoms requires careful examination of available evidence and clinical experience

The FDA has stated that compounded BPC-157 may present immunogenicity and peptide-characterization risks and that available safety information is insufficient to determine whether proposed uses could harm humans